A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
Completed · Phase 3 · NCT06602726
Conditions: Allergic Conjunctivitis
At a glance
- Research payments reported, 2025
- $934,935
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 64
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN1908 (drug), REGN1909 (drug), Placebo (drug)
- Dates
- Started 2024-11-06; completion 2025-08-02
- Results posted
- Not yet
This study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy. The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effecti…
From ClinicalTrials.gov, last updated 2026-05-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $934,935 in research payments for this study in 2025 (1,182 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Andover Eye Associates Inc $581,007
- Aapri Clinical Research Institute $353,927
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.